{"id":6510,"date":"2023-04-11T19:30:03","date_gmt":"2023-04-11T19:30:03","guid":{"rendered":"http:\/\/lynettelockhart.com\/client\/moderna-fends-off-arbutus\/"},"modified":"2023-04-12T23:48:37","modified_gmt":"2023-04-12T23:48:37","slug":"moderna-fends-off-arbutus","status":"publish","type":"post","link":"http:\/\/lynettelockhart.com\/client\/moderna-fends-off-arbutus\/","title":{"rendered":"Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight"},"content":{"rendered":"<p>(Reuters) -A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies&#8217; legal fight over Moderna&#8217;s blockbuster COVID-19 vaccines.<\/p>\n<p>The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal&#8217;s ruling that the patent for Arbutus&#8217; lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.<\/p>\n<p>Moderna challenged the patent at the PTO&#8217;s Patent Trial and Appeal Board in 2018, and the board invalidated it in 2019.<\/p>\n<p>A spokesperson for Genevant declined to comment on the Tuesday decision. A Moderna spokesperson said the company was pleased with the ruling.<\/p>\n<p>The Federal Circuit&#8217;s decision does not affect an ongoing lawsuit filed by Arbutus and Genevant Sciences \u2014 a joint venture between Arbutus and Roivant Sciences Ltd \u2014 against Moderna last year in Delaware for allegedly infringing other related LNP patents.<\/p>\n<p>Warminster Township, Pennsylvania-based Arbutus said in the lawsuit that Cambridge, Massachusetts-based Moderna began challenging its patents at the PTO after failing to acquire a license to its LNP technology. <\/p>\n<p>The technology is used to deliver RNA to target cells without being attacked by the body&#8217;s immune system. <\/p>\n<p>Arbutus separately sued Pfizer and BioNTech for patent infringement last week over their COVID-19 shots, in a lawsuit that also does not include the canceled patent.<\/p>\n<p>The Federal Circuit case is Arbutus Biopharma Corp v. ModernaTX Inc, U.S. Court of Appeals for the Federal Circuit, No. 20-1183.<\/p>\n<p> (Reporting by Blake Brittain in Washington)<\/p>\n<p><a href=\"http:\/\/lynettelockhart.com\/client\/moderna-fends-off-arbutus\/file-photo-people-receive-covid-19-boosters-targeting-omicron\/\"><img decoding=\"async\" src=\"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ3A0MX-VIEWIMAGE.jpg\" alt=\"tagreuters.com2023binary_LYNXMPEJ3A0MX-VIEWIMAGE\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) -A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies&#8217; legal fight over Moderna&#8217;s blockbuster COVID-19 vaccines. The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal&#8217;s ruling that the patent for [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":6511,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","footnotes":""},"categories":[1213],"tags":[1223],"class_list":["post-6510","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-u-s-business","tag-updated"],"jetpack_featured_media_url":"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ3A0MX-VIEWIMAGE.jpg","_links":{"self":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/6510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/comments?post=6510"}],"version-history":[{"count":3,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/6510\/revisions"}],"predecessor-version":[{"id":8337,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/6510\/revisions\/8337"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media\/6511"}],"wp:attachment":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media?parent=6510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/categories?post=6510"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/tags?post=6510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}